Debilitating Symptom Complexes Attributed to Ticks (DSCATT) is a new term for an unexplained Australian syndrome—people who suffer from a chronic, multifaceted and debilitating illness, characteristically attributed to tick bites, but in a country without endemic Lyme disease. Despite the profound morbidity of DSCATT, no single causative agent has been identified and there are no recognised treatments for the illness at present. An increasing body of evidence shows psychological therapies such as Acceptance and Commitment Therapy (ACT) can be effective in reducing symptom-related disability and improving quality of life for other unexplained syndromes. Here we present a study protocol to assess the feasibility of an ACT-informed intervention for patients suffering from DSCATT, to be used adjunctively to their pre-existing healthcare. The study aims to assess the acceptability, practicality and demand for the treatment. Additionally, we will examine the effects of therapy on participants’ health and well-being, its safety, potential mediators of response to therapy and its preliminary cost-effectiveness.

We will assess the feasibility of a 32-week, randomised, waitlist-controlled, parallel convergent mixed-methods pilot trial for DSCATT. Participants will be randomised in a 1:1 ratio to receive either 16 sessions of ACT-informed therapy adjunctive to their pre-existing healthcare, delivered one-to-one with a trial therapist within a 20-week period or be assigned to the waitlist control group where they will continue their treatments as usual. We will collect quantitative and qualitative data to address study aims, with retention rate being the primary feasibility outcome.

The study has ethical approval from Austin Health Human Research Ethics Committee (HREC). The outcomes will be published in peer-reviewed journals. Data from participants who have given extended consent will be available for other HREC-approved studies.

ACTRN12623000372684, prospectively registered 13 April 2023, URL: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385579&isReview=true; the last participant is expected to complete in November 2026.

Functional seizures (FS) are events that resemble epileptic seizures, but are not attributed to brain pathology and are instead thought to be due to psychological factors. A small, multisite, open-label, single-arm, pilot trial of a breathing intervention known as breathing control training (BCT) found it to be safe and effective in reducing seizure frequency in FS. We propose a protocol for a study to confirm these results.

A 24-week, multicentre, individually-randomised, assessor-blinded, two-arm, parallel-group efficacy and acceptability trial of BCT versus control (Befriending) in 220 participants ≥16 years of age with FS. Eligible participants will be randomly allocated to receive two sessions of either BCT or Befriending over a 4-week period. Sessions will be delivered by a respiratory physiotherapist at a clinical care site or via telehealth. They will complete assessments prior to commencing treatment and at 4, 12 and 24 weeks after their initial session of BCT/Befriending. The trial will be conducted alongside treatment as usual. An economic evaluation including cost-utility and cost-effectiveness analyses will be carried out from health sector and societal perspectives.

The study has been approved by The Austin Health Human Research Ethics Committee (HREC/84335/Austin-2022) and the New Zealand Central Health and Disability Ethics Committee (2022 FULL 12324). Findings will be reported to trial participants and consumers; presented at local, national and international conferences; and disseminated by a peer-reviewed scientific journal.

Self-rated health (SRH) is a well-established predictor of all-cause mortality. However, its predictive value in patients with cancer remains unclear. We aimed to elucidate the relationship between prediagnostic SRH and mortality among patients with cancer using data from the Norwegian Women and Health (NOWAC) Study.

A prospective cohort study.

This study included 26 405 women from the NOWAC cohort who were diagnosed with cancer between 1992 and 2020. Subgroup analyses focused on the most common cancer types among Norwegian women: breast (n=8299), colorectal (n=3653) and lung and bronchial (n=2428) cancers.

Prediagnostic SRH was assessed using a single-item measure with four response alternatives and categorised into ‘very good’, ‘good’ and ‘poor’ SRH. We used flexible parametric survival analysis and competing risk regression models to evaluate the association between SRH and all-cause and cancer-specific mortality after adjusting for age, physical activity, Body Mass Index, smoking, alcohol consumption and education.

Poor prediagnostic SRH was associated with increased all-cause mortality among long-term cancer survivors. For specific cancer sites, the adjusted HRs and 95% CI for poor versus very good SRH were 1.29 (95% CI: 1.06 to 1.58) for breast cancer and 1.50 (95% CI: 1.20 to 1.88) for colorectal cancer. These associations were more pronounced among long-term survivors than short-term survivors. No association was observed between prediagnostic SRH and mortality for patients with lung cancer. For cancer-specific mortality, prediagnostic SRH predicted mortality from all cancers, as well as from colorectal cancer.

Prediagnostic SRH is a significant predictor of mortality in patients with cancer, particularly among long-term survivors. These findings indicate the potential of SRH as a predictive tool for mortality, underscoring the importance of integrating SRH assessments into identifying individuals at higher risk of mortality and highlighting the potential benefits of public health interventions aimed at improving overall health, but further studies are required to assess the effect of such interventions on SRH.